Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

This year. We're going Beyond.

Why is the Healius (ASX:HLS) share price rising?

The last time the Healius Limited (ASX: HLS) share price was hovering at current levels was in 2018 when the winter Olympic games was in Korea.

What has happened to the Healius share price since then and how will the recent trading update impact it?

Healius is a healthcare business that provides pathology, diagnostic imaging, medical centres and low-cost fertility services, such as IVF.

HLS share price

Source: Rask Media HLS 5-year share price chart

Solid growth across the pathology segment

In terms of COVID testing, Healiys recently reached 3 million COVID tests in total with over 800,000 completed in the third quarter (Q3) of FY21. This was consistent with the first half of FY21 (1H FY21).

Healius notes commercial COVID testing is growing.

In relation to non-COVID revenue, this is 5% ahead of the prior corresponding period (PCP) in Q3 FY20 and growing compared to 1H FY21.

Imaging segment grows as well

The imaging segment recorded a jump of 8% on the PCP and Victoria is showing signs of progressive recovery.

Hospitals experience growth

There was continual growth in the hospitals segment as it surged by 25% relative to PCP, which was driven by Montserrat.

Also, Westside Private Hospital performed close to 1,000 procedures in March, its best month to-date, and successfully completed its first hip and knee replacement surgeries.

Healius noted the Adora Fertility continued to trade profitably.

My thoughts

Whilst its important to monitor growth in revenue, investors should also consider monitoring its competitors.

It competes with Sonic Healthcare Limited (ASX: SHL) and Capitol Health Ltd (ASX: CAJ).

It seems Healius was a big beneficiary of the pandemic, so the key question is whether this segment will continue over the long term.

Given the rise in revenue since the pandemic, it’s not surprising that the Price to Earnings ratio (P/E ratio explained) is higher than the industry average.

Whilst testing remains important in a lot of countries, I think testing will steadily reduce over time as the vaccine rolls out.

As a result, I think growth will likely taper off over the long term.

If you are interested in other ASX growth shares, I suggest getting a Rask account and accessing our full stock reports. Click this link to join for free.

Got $1,000? Try our #1 growth stock...

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or enter your email below. We'll send you the report.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Got $1,000? Try this...

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or the button below. We'll email you the report.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading: